Progress of researches on the differential diagnosis of Pneumocystis jiroveci infection and colonization

doi:10.16352/j.issn.1001-6325.2025.01.0116

Abstract

Abstract: Pneumocystis jiroveci(PJ) is an atypical conditional pathogenic fungus. PJ colonization is a potential risk factor for Pneumocystis jiroveci pneumonia (PJP). Active identification of PJ colonization or infection is conducive to rational use of antibiotics. Although serum G test combined with molecular detection technology, peripheral blood CD4⁺ T level and independent characterization of trophozoites and cysts by transcriptome sequencing technology may support identifying PJ colonization and diagnosis of infection, unified standards have not yet been established. Based on the pathogenic characteristics and pathogenic mechanism of PJ,clinical characteristics and diagnostic methods of PJP, this paper reviews the progress of differential diagnosis of PJ infection and colonization, so as to provide more objective and comprehensive differential strategy for clinical diagnosis and treatment.

Key words: Pneumocystis jroveci, Pneumocystis jroveci pneumonia, colonization, diagnosis, differential diagnosis

CLC Number:

R563.1

LI Xingchen, TONG Jin. Progress of researches on the differential diagnosis of Pneumocystis jiroveci infection and colonization[J]. Basic & Clinical Medicine, 2025, 45(1): 116-120.

References

[1] Cao Y, Chen J, Dong L. Supplementary role of immunological indicators in the diagnosis and prognosis of pneumocystis pneumonia in non-HIV immunocompromised patients[J]. Infect Drug Resist, 2022, 15: 4675-4683.
[2] Benedict K, Baggs J, Gold J. Epidemiology, clinical characteristics, and diagnostic testing practices for pneumocystis pneumonia-associated hospitalizations, United States, 2019-2022[J]. Open Forum Infect Dis, 2024, 11: ofae54. doi: 10.1093/ofid/ofae054.
[3] Riebold D, Mahnkopf M, Wicht K, et al. Axenic long-term cultivation of Pneumocystis jirovecii[J]. J Fungi (Basel), 2023, 9. doi: 10.3390/jof9090903.
[4] Kottom TJ, Carmona EM, Limper AH. Gene expression in lung epithelial cells following interaction with Pneumocystis carinii and its specific life forms yields insights into host gene responses to infection[J]. Microbiol Immunol, 2022, 66: 238-251.
[5] Weissenbacher-Lang C, Blasi B, Bauer P, et al. Detection of pneumocystis and morphological description of fungal distribution and severity of infection in thirty-six mammal species[J]. J Fungi (Basel), 2023, 9. doi: 10.3390/jof9020220.
[6] Elango K, Mudgal M, Murthi S, et al. Trends in the epidemiology and outcomes of pneumocystis pneumonia among human immunodeficiency virus (HIV) hospitalizations[J]. Int J Environ Res Public Health, 2022,19. doi: 10.3390/ijerph19052768.
[7] Huang MQ, Zheng TT, Wang XR, et al. The clinical value of metagenomic next-generation sequencing in Pneumocystis jirovecii pneumonia[J]. Infect Drug Resist, 2024, 17: 69-80.
[8] Liu Y, Wang X, Xu J, et al. Diagnostic value of metagenomic next-generation sequencing of lower respiratory tract specimen for the diagnosis of suspected Pneumocystis jirovecii pneumonia[J]. Ann Med, 2023, 55: 2232358. doi: 10.1080/07853890.2023.2232358.
[9] Costa JM, Botterel F, Cabaret O, et al. Association between circulating DNA, serum (1-＞3)-beta-D-glucan, and pulmonary fungal burden in Pneumocystis pneumonia[J]. Clin Infect Dis, 2012, 55: e5-e8.
[10] Esteves F, Cale SS, Badura R, et al. Diagnosis of pneumocystis pneumonia: evaluation of four serologic biomarkers[J]. Clin Microbiol Infect, 2015, 21: 371-379.
[11] Li X, Li Z, Ye J, et al. Diagnostic performance of metagenomic next-generation sequencing for Pneumocystis jirovecii pneumonia[J]. BMC Infect Dis, 2023, 23: 455. doi: 10.1186/s12879-023-08440-4.
[12] Le Gal S, Bonnet P, Huguenin A, et al. The shift from pulmonary colonization to Pneumocystis pneumonia[J]. Med Mycol, 2021, 59: 510-513.
[13] de la Horra C, Friaza V, Morilla R, et al. Update on dihydropteroate synthase (DHPS) mutations in Pneumo-cystis jirovecii[J]. J Fungi (Basel), 2021, 7. doi: 10.3390/jof7100856.
[14] Board KF, Patil S, Lebedeva I, et al. Experimental Pneumocystis carinii pneumonia in simian immunodefici-ency virus-infected rhesus macaques[J]. J Infect Dis, 2003, 187: 576-588.
[15] Tan SJ, Pryce TM, Haygarth EJ, et al. Quantitative Pneumocystis jirovecii real-time PCR to differentiate disease from colonisation[J]. Pathology, 2021, 53: 896-901.
[16] Veintimilla C, Alvarez-Uria A, Martin-Rabadan P, et al. Pneumocystis jirovecii pneumonia diagnostic approach: real-life experience in a tertiary centre[J]. J Fungi (Basel), 2023, 9(4). doi: 10.3390/jof9040414.
[17] Sarasombath PT, Thongpiya J, Chulanetra M, et al. Quantitative PCR to discriminate between pneumocystis pneumonia and colonization in HIV and non-HIV immunocompromised patients[J]. Front Microbiol, 2021, 12: 729193. doi: 10.3389/fmicb.2021.729193.
[18] Damiani C, Le Gal S, Da CC, et al. Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1-＞3)-beta-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization[J]. J Clin Microbiol, 2013, 51: 3380-3388.
[19] Bian W, Shang Y, Zhao L, et al. Clinical performance of BALF droplet digital PCR for differential diagnosis of Pneumocystis jirovecii pneumonia and Pneumocystis jirovecii colonization[J]. Diagn Microbiol Infect Dis, 2024, 108: 116168. doi: 10.1016/j.diagmicrobio.2023.116168.
[20] Liu L, Yuan M, Shi Y, et al. Clinical performance of BAL metagenomic next-generation sequence and serum (1,3)-beta-D-glucan for differential diagnosis of Pneumocystis jirovecii pneumonia and Pneumocystis jirovecii colonisation[J]. Front Cell Infect Microbiol, 2021, 11: 784236. doi: 10.3389/fcimb.2021.784236.
[21] 张彩霞,刘新年,杜川,等. mNGS技术和血清G试验在判断耶氏肺孢子菌感染与定植中的价值及二者相关性研究[J]. 中国全科医学, 2023, 26: 1355-1360.
[22] Hauser PM. Pneumocystis mating-type locus and sexual cycle during infection[J]. Microbiol Mol Biol Rev, 2021, 85: e921. doi: 10.1128/MMBR.00009-21.
[23] Shimizu Y, Sunaga N, Dobashi K, et al. Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study[J]. BMC Infect Dis, 2009, 9: 47. doi: 10.1186/1471-2334-9-47.
[24] Shellito JE, Tate C, Ruan S, et al. Murine CD4⁺ T lymphocyte subsets and host defense against Pneumocystis carinii[J]. J Infect Dis, 2000, 181: 2011-2017.
[25] Eddens T, Elsegeiny W, Ricks D, et al. Transcriptomic and proteomic approaches to finding novel diagnostic and immunogenic candidates in pneumocystis[J]. mSphere, 2019, 4. doi: 10.1128/mSphere.00488-19.